Blair William & Co. IL Decreases Stake in Exact Sciences Co. (NASDAQ:EXAS)

Blair William & Co. IL reduced its position in Exact Sciences Co. (NASDAQ:EXASFree Report) by 2.2% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 378,129 shares of the medical research company’s stock after selling 8,587 shares during the quarter. Blair William & Co. IL owned about 0.21% of Exact Sciences worth $25,796,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Exact Sciences by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock worth $541,823,000 after purchasing an additional 698,740 shares during the period. Capital World Investors grew its stake in shares of Exact Sciences by 2.6% during the 2nd quarter. Capital World Investors now owns 6,797,960 shares of the medical research company’s stock worth $638,328,000 after purchasing an additional 173,174 shares during the period. Artisan Partners Limited Partnership grew its stake in shares of Exact Sciences by 11.8% during the 3rd quarter. Artisan Partners Limited Partnership now owns 3,961,514 shares of the medical research company’s stock worth $270,254,000 after purchasing an additional 418,770 shares during the period. Geode Capital Management LLC boosted its position in shares of Exact Sciences by 4.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,696,040 shares of the medical research company’s stock worth $252,753,000 after buying an additional 104,983 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Exact Sciences by 8.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,666,008 shares of the medical research company’s stock worth $113,655,000 after buying an additional 133,945 shares in the last quarter. 89.13% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Trading Down 0.6 %

EXAS opened at $60.64 on Friday. The firm has a 50 day moving average price of $67.49 and a 200 day moving average price of $71.11. Exact Sciences Co. has a 1 year low of $58.43 and a 1 year high of $100.77. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.41 and a quick ratio of 2.13.

Insider Buying and Selling

In related news, insider Brian Baranick sold 879 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.50, for a total transaction of $64,606.50. Following the completion of the sale, the insider now owns 7,992 shares of the company’s stock, valued at approximately $587,412. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.50, for a total value of $147,000.00. Following the completion of the sale, the executive vice president now owns 69,423 shares of the company’s stock, valued at $5,102,590.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian Baranick sold 879 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.50, for a total transaction of $64,606.50. Following the completion of the sale, the insider now directly owns 7,992 shares of the company’s stock, valued at approximately $587,412. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,879 shares of company stock valued at $351,607. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

EXAS has been the topic of several recent research reports. Piper Sandler decreased their price objective on shares of Exact Sciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, October 16th. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Monday, January 8th. Wolfe Research initiated coverage on shares of Exact Sciences in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $95.00 price objective on the stock. TheStreet upgraded shares of Exact Sciences from a “d+” rating to a “c-” rating in a research report on Tuesday, January 9th. Finally, The Goldman Sachs Group reduced their target price on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $97.06.

Read Our Latest Report on Exact Sciences

Exact Sciences Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

See Also

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.